Extracellular matrix remodeling in anthracycline-induced cardiotoxicity: What place on the pedestal?-Reference-Cited by-同舟云学术

Extracellular matrix remodeling in anthracycline-induced cardiotoxicity: What place on the pedestal?

Published:2022-03 Issue: Volume:350 Page:55-61
ISSN:0167-5273
Container-title:International Journal of Cardiology
language:en
Short-container-title:International Journal of Cardiology

Author:

Grakova Elena V.,Shilov Sergey N.,Kopeva Kristina V.,Berezikova Ekaterina N.,Popova Anna A.,Neupokoeva Maria N.,Ratushnyak Elena T.,Teplyakov Alexander T.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference32 articles.

1. Risk and temporal changes of heart failure among 5-year childhood cancer survivors: a DCOG-LATER study;Feijen;J. Am. Heart Assoc.,2019

2. Anthracycline-dependent cardiotoxicity and extracellular matrix remodeling;Nikitovic;Chest.,2014

3. Extracellular matrix remodeling in animal models of anthracycline-induced cardiomyopathy: a meta-analysis;Leerink;J. Mol. Med. (Berl.),2021

4. TIMPs and cardiac remodeling: ‘embracing the MMP-independent-side of the family’;Vanhoutte;J. Mol. Cell. Cardiol.,2010

5. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches;Schulz;Annu. Rev. Pharmacol. Toxicol.,2007

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Possibilities of dapagliflozin-induced cardioprotection on doxorubicin + cyclophosphamide mode of chemotherapy-induced cardiomyopathy;International Journal of Cardiology;2023-11

2. Prognostic value of humoral markers in patients with anthracycline-related cardiac dysfunction;Bulletin of Siberian Medicine;2023-10-17

3. Emerging role of PET/MR in the diagnosis and characterization of cardiotoxicity?;International Journal of Cardiology;2023-08

4. New Insights in the Era of Clinical Biomarkers as Potential Predictors of Systemic Therapy-Induced Cardiotoxicity in Women with Breast Cancer: A Systematic Review;Cancers;2023-06-22

5. Tetranectin as a potential novel prognostic biomarker in anthracycline-related cardiac dysfunction;Heart and Vessels;2023-06-13